BioCardia Inkomsten in het verleden
Verleden criteriumcontroles 0/6
BioCardia has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 9.8% per year.
Belangrijke informatie
7.8%
Groei van de winst
41.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 9.8% |
Rendement op eigen vermogen | n/a |
Nettomarge | -1,999.8% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
May 14Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12BioCardia stock rises on contract for delivery products for BlueRock's cell therapies
Aug 24Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Aug 24Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
May 10We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Jan 06We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Sep 23Opbrengsten en kosten
Hoe BioCardia geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -9 | 4 | 0 |
31 Mar 24 | 0 | -10 | 4 | 0 |
31 Dec 23 | 0 | -12 | 4 | 0 |
30 Sep 23 | 1 | -13 | 4 | 0 |
30 Jun 23 | 0 | -13 | 4 | 0 |
31 Mar 23 | 1 | -12 | 4 | 0 |
31 Dec 22 | 1 | -12 | 4 | 0 |
30 Sep 22 | 1 | -12 | 5 | 0 |
30 Jun 22 | 2 | -12 | 5 | 0 |
31 Mar 22 | 1 | -13 | 5 | 0 |
31 Dec 21 | 1 | -13 | 5 | 0 |
30 Sep 21 | 1 | -12 | 5 | 0 |
30 Jun 21 | 0 | -13 | 5 | 0 |
31 Mar 21 | 0 | -13 | 5 | 0 |
31 Dec 20 | 0 | -15 | 6 | 0 |
30 Sep 20 | 0 | -16 | 6 | 0 |
30 Jun 20 | 0 | -15 | 6 | 0 |
31 Mar 20 | 1 | -16 | 6 | 0 |
31 Dec 19 | 1 | -15 | 6 | 0 |
30 Sep 19 | 1 | -15 | 6 | 0 |
30 Jun 19 | 0 | -15 | 6 | 0 |
31 Mar 19 | 1 | -14 | 6 | 0 |
31 Dec 18 | 1 | -14 | 6 | 0 |
30 Sep 18 | 1 | -14 | 6 | 0 |
30 Jun 18 | 1 | -13 | 6 | 0 |
31 Mar 18 | 1 | -13 | 6 | 0 |
31 Dec 17 | 0 | -12 | 6 | 0 |
30 Sep 17 | 1 | -12 | 6 | 0 |
30 Jun 17 | 1 | -13 | 6 | 0 |
31 Mar 17 | 1 | -12 | 5 | 0 |
31 Dec 16 | 1 | -10 | 4 | 0 |
30 Sep 16 | 1 | -7 | 3 | 0 |
30 Jun 16 | 1 | -7 | 3 | 0 |
31 Mar 16 | 1 | -6 | 3 | 0 |
31 Dec 15 | 1 | -7 | 4 | 0 |
31 Mar 15 | 1 | -10 | 5 | 0 |
31 Dec 14 | 1 | -10 | 4 | 0 |
31 Dec 13 | 2 | -6 | 3 | 0 |
Kwaliteitswinsten: BCDA is currently unprofitable.
Groeiende winstmarge: BCDA is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BCDA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Versnelling van de groei: Unable to compare BCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BCDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: BCDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.